go-v.orgdoi

Sodium–glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials

Mark S. Kipnes · Clinical Investigation · 2011

  • DOI 10.4155/cli.10.12
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

As a result of the progressive nature of Type 2 diabetes, novel, insulin-independent therapies are needed to reduce blood glucose, without increasing body weight. A new class of investigational drugs, sodium–glucose cotransporter 2 (SGLT2) inhibitors, remove glucose from circulation via the kidney. Several SGLT2 inhibitors in development (dapagliflozin, canagliflozin, ASP1941, BI10773 and LX4211) have demonstrated improvement in glycemic control and weight loss.

Because renal glucose reabsorption is independent of insulin action or secretion, SGLT2 inhibition may be a versatile mechanism with utility as monotherapy and in combination with oral antidiabetics and/or insulin, and has a low potential for hypoglycemia. Heightened concern over the long-term cardiovascular risks posed by hypoglycemia as well as obesity may eventually drive the use of this class earlier in the treatment paradigm.

Open the resolved locator · 10.4155/cli.10.12

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 10:30 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.10.12
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.